Does Urolithin A Work? The Honest Read on Industry-Funded Trials
Educational summary — not medical advice. No human trial has tested urolithin A for lifespan extension, anti-aging, or disease outcomes at any dose. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
Five of the seven human trials behind urolithin A's muscle-endurance evidence are funded by Amazentis SA — the company that owns the Mitopure brand and the underlying patents. Only Zhao 2024 is fully independent. The biological rationale for supplementing directly (rather than relying on diet) is genuine: most adults are unreliable natural producers of urolithin A from food. The clinical signal itself is real and modestly replicated across populations — but it is disclosed here as coming almost entirely from research funded by the party with the clearest financial stake in a positive result, with no lifespan or disease-outcome data at any dose.
Part 1: the producer-biology rationale (genuine, not marketing)
Before getting to the funding question, it's worth understanding why direct urolithin A supplementation exists as a category at all, separate from "eat more pomegranates." Urolithin A isn't found pre-formed in food in meaningful amounts — it's a metabolite that gut bacteria produce from ellagitannins, compounds found in pomegranates, walnuts, and some berries. Singh 2021 tested this directly in over 100 healthy adults: after a pomegranate-juice challenge, only about 12% had any detectable urolithin A at baseline, and only around 40% of participants turned out to be reliable "producers" who could convert a meaningful amount of dietary ellagitannins into urolithin A via their gut microbiome at all. Direct oral urolithin A supplementation, by contrast, gave more than 6-fold higher and far more consistent plasma exposure than the pomegranate juice, independent of a person's natural producer status. That's a real, non-marketing biological reason direct supplementation might matter — it bypasses a gut-bacteria bottleneck that a majority of people apparently have. It is important to be precise about what this trial does and doesn't show, though: it's a bioavailability and pharmacokinetics study, not an efficacy trial. It explains why a pill might reach the bloodstream more reliably than pomegranate juice; it says nothing about whether reaching the bloodstream produces a clinical benefit. That question belongs to the trials in Part 2.
Part 2: the funding roster, counted explicitly
This is the single most important table on this site for urolithin A, because it changes how every other claim on this cluster should be read. Of the seven human trials in this evidence base:
| Study | Funding | What it tested |
|---|---|---|
| Andreux 2019 | Amazentis-funded — authors include the Amazentis founder/CEO and employees | First-in-human safety/PK, n=60 |
| Singh 2021 | Amazentis-funded — same author/employee set | Producer-biology/bioavailability (not efficacy) |
| Liu 2022 | Partially Amazentis-funded/co-authored (3 of 9 authors); lead site independent (University of Washington) | Sedentary older adults, n=66 |
| Singh 2022 | Fully Amazentis-funded — every author is a current/former Amazentis employee, board member, or advisor; paper states Amazentis "is the sponsor" | Untrained middle-aged adults, n=88 — the strongest positive trial in this pack |
| Zhao 2024 | FULLY INDEPENDENT — Jiangsu Province educational grant, explicit no-COI disclosure | Young trained athletes, n=20 — the one non-Amazentis trial |
| Whitfield 2025 | Amazentis-funded — 3 co-authors are Amazentis employees | Elite distance runners, n=42 |
| Monsalve Acevedo 2025 | Partially industry-adjacent — one author received travel reimbursement from the Mitopure manufacturer; primary grant unrelated (Memphasys) | Adolescent soccer players (pilot), n=20 |
5 of 7 trials are Amazentis-funded and/or Amazentis-employee-co-authored in whole or part. 1 of 7 (Zhao 2024) is fully independent. 1 of 7 (the soccer pilot) has partial, narrower industry-adjacent funding that shouldn't be lumped in with the fully-funded trials, but also isn't the same as full independence. This isn't disqualifying — industry-funded trials can be rigorous, and Singh 2022's methodology and reporting are solid by normal clinical-trial standards. But a reader deserves to know, before reading any positive finding, that the company selling the ingredient funded or staffed most of the research proving it works. Zhao 2024 pointing the same general direction on endurance is genuinely reassuring — independent confirmation, even partial and small-scale, is exactly the kind of evidence that should carry extra weight. It's one trial, though, in one narrow population (n=20, young already-trained athletes), not a large-scale independent replication.
Part 3: the verdict
A real, replicated, modest-effect-size signal on muscle endurance and fatigue resistance — more consistent across trials than raw maximal-strength gains — disclosed honestly as coming almost entirely from the company that profits from a positive result. Two of the industry-funded trials (Liu 2022, Whitfield 2025) had null primary endpoints, with the positive findings landing on secondary measures; that ordering is named throughout this cluster rather than skipped past. The safety profile is genuinely reassuring — no serious adverse events across any trial, up to 2,000mg as a single dose or 1,000mg/day for 4 months — the longest continuous human safety window in this site's newer-longevity category, even though it still falls short of a 6-month-plus long-term read. And there is no lifespan, anti-aging, or disease-outcome data at any dose, in any trial, funded or independent.
The one-line takeaway Urolithin A has genuinely more human RCT evidence behind it than most longevity-marketed ingredients — and 5 of those 7 trials were funded by the one company that stood to profit from a positive result. Zhao 2024's independent confirmation on endurance is real and worth weighting, but it's one small trial, not a large-scale replication. Read the funding line before the finding, on this page and every other page in this cluster.
Frequently asked questions
Why do most people need to supplement instead of eating pomegranates?
Only ~40% of adults reliably produce urolithin A from dietary ellagitannins (Singh 2021); direct supplementation gives 6x+ more consistent plasma exposure. A bioavailability finding, not an efficacy claim on its own.
How many trials are funded by the company that sells it?
5 of 7 are Amazentis-funded and/or employee-co-authored in whole or part. Only Zhao 2024 is fully independent.
What is the one independent trial, and what did it find?
Zhao 2024 (Jiangsu grant, no COI): functional endurance improved, maximal strength (1RM) did not, in young trained athletes (n=20).
Does urolithin A work?
A real, modest, replicated muscle-endurance signal — disclosed as coming almost entirely from industry-funded research, with no lifespan or disease data at any dose.
Related
- Urolithin A: what it is & the funding count
- Urolithin A for muscle & exercise endurance — the full population-by-population breakdown
- Urolithin A dosage guide — 500-1,000mg trial range vs the shelf
- Best urolithin A — the honest retail-landscape guide
Sources
- Andreux PA, Blanco-Bose W, Ryu D, et al. "The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans." Nat Metab. 2019. PMID: 32694802
- Singh A, Andreux PA, Blanco-Bose W, et al. "Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variation." Eur J Clin Nutr. 2021. PMID: 34117375
- Liu S, D'Amico D, Shankland E, et al. "Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial." JAMA Netw Open. 2022. PMID: 35050355
- Singh A, D'Amico D, Andreux PA, et al. "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults." Cell Rep Med. 2022. PMID: 35584623
- Zhao J, Zhu J, Yun H, et al. "Effects of urolithin A supplementation on muscle endurance, strength, and inflammatory biomarkers in trained young athletes." J Int Soc Sports Nutr. 2024. PMID: 39487653
- Whitfield J, et al. "Urolithin A Supplementation in Highly-Trained Distance Runners During an Altitude Training Camp." Sports Med. 2025. PMID: 40839339
- Monsalve Acevedo N, et al. "Urolithin A supplementation in adolescent academy soccer players: a pilot study." Front Nutr. 2025. PMID: 41245402